CAMCI: Advancing the Use of Computerized Screening in Healthcare

老年人群的认知功能障碍，从简单的健忘到诊断为 阿尔茨海默病会影响一个人的生活质量和日常活动能力。至关重要的是 尽早发现下降，以评估原因是否可治疗，并使用 适当的治疗，如果适用。大多数老年患者依赖于他们的初级保健医生 他们的大部分医疗保健需求，但医生缺乏可用的敏感工具，而且 是医生没有时间使用可用的工具，导致无法提供治疗 在损失的最早阶段进行干预，可能会减缓疾病的进展。有一种明确的 需要一种简单易用的评估工具，旨在针对早期认知能力下降，并需要 将该工具介绍给最常照顾老年人的提供者：初级保健医生 (PCPS)。心理学软件工具公司(PST)已经开发了这样一个工具，即计算机评估 记忆和认知障碍(CAMCI)，一种检测早期体征的计算机化筛查工具 认知功能下降，这已被证明在识别细微疾病患者方面更有效 认知损失比PCP办公室内最常用的工具(即MMSE)更高。随着太平洋标准时间的可观 在电脑化测试和老年人口工作方面的经验，并符合PST的要求 公司的使命是推动研究和评估领域的发展，CAMCI将为 初级保健医生和临床医生在诊断痴呆症之前提供治疗干预。最近增加的内容 CPT代码允许对计算机进行的神经心理测试进行保险报销，包括时间 供内科医生或临床心理学家进行解读和报告。这项新收入的引入 针对PCP和临床医生的流，加上简短和自行给药的特点 CAMCI是改善早期干预的有吸引力的选择，为以下方面提供智能业务解决方案 医疗保健专业人员，以及使医生能够更好地评估和服务的有用和有效的工具 他们的病人。当前项目中包括的具体目标侧重于以下活动 通过扩展对后期研究和产品的支持，成功地将CAMCI推向商业化 发展，包括监管战略和知识产权发展，数据收集以复制 重点研究，通过增加少数族裔代表来扩大产品范围，并制定措施 有意义的改变。最终目标是简化CAMCI的商业化，并提供 医生是大多数认知功能障碍的提供者，是检测认知功能障碍的有用和有效的工具 为老年人群提供医疗保健，以提高临床实践的效率和效果。

Cognitive dysfunction in the elderly population, ranging from simple forgetfulness to a diagnosis of Alzheimer’s disease, can impact one’s quality of life and ability to function in daily activities. It is crucial that decline be detected as early as possible in order to evaluate whether the cause is treatable, and to employ appropriate treatment, if applicable. The majority of older patients rely on their primary care physician for the bulk of their healthcare needs, but there is a lack of sensitive tools available to the physician, and there is a lack of physician’s time to use the tools that are available, leading to a failure to provide therapeutic intervention at the earliest stages of loss to potentially slow the progression of disease. There is a clear need for an easy-to-use and brief assessment tool designed to target early cognitive decline, and a need to introduce the tool to providers who most frequently care for the elderly population: Primary Care Physicians (PCPs). Psychology Software Tools, Inc. (PST) has developed such a tool, the Computer Assessment of Memory and Cognitive Impairment (CAMCI), a computerized screening tool for the detection of early signs of cognitive decline, which has been shown to be more effective in the identification of patients with subtle cognitive loss than the tool most frequently used within the PCP office (i.e., MMSE). With PST’s considerable experience in computerized testing and working with older populations, and in accordance with PST’s company mission to advance the fields of research and assessment, CAMCI would provide an option for PCPs and clinicians to provide therapeutic intervention prior to a diagnosis of dementia. Recent additions to CPT codes permit insurance reimbursement for neuropsychological testing by a computer, including time for the physician's or clinical psychologist's interpretation and reporting. The introduction of this new revenue stream for PCPs and clinicians, coupled with the characteristics of being brief and self-administered make CAMCI an attractive option for improving early intervention, providing an intelligent business solution for healthcare professionals, and a useful and effective tool that allows physicians to better evaluate and serve their patients. The specific aims included in the current project are focused on activities required to successfully move CAMCI to commercialization by extending support for late stage research and product development, including regulatory strategy and intellectual property development, data collection to replicate key studies, product extension through increasing minority representation, and development of a measure of meaningful change. The ultimate goal is to streamline the commercialization of CAMCI, and to provide a useful and effective tool in the detection of cognitive dysfunction to physicians, the providers of the majority of healthcare to the elderly population, to improve efficiency and effectiveness of clinical practice.